Abstract
During
the last decades, photodynamic therapy (PDT), an approved medical
technique, has received increasing attention to treat certain types of
cancer. Despite recent improvements, the treatment of large tumors
remains a major clinical challenge due to the low ability of the
photosensitizer (PS) to penetrate a 3D cellular architecture and the low
oxygen concentrations present in the tumour centre. To mimic the
conditions found in clinical tumors, exceptionally large 3D
multicellular tumour spheroids (MCTSs) with a diameter of 800 µm were
used in this work to test a series of new Ru(II) polypyridine complexes
as 1-Photon and 2-Photon PSs. These metal complexes were found to fully
penetrate the 3D cellular architecture and to generate singlet oxygen in
the hypoxic centre upon light irradiation. While having no observed
dark toxicity, the lead compound of this study showed an impressive
phototoxicity upon clinically relevant 1-Photon (595 nm) or 2-Photon
(800 nm) excitation with a full eradication of the hypoxic centre of the
MCTSs. Importantly, this efficacy was also demonstrated on mice bearing
an adenocarcinomic human alveolar basal epithelial tumour.
Supplementary materials
Title
SI
Description
Actions